Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

VP Chavda, LK Vora, AK Pandya, VB Patravale - Drug discovery today, 2021 - Elsevier
Abstract Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines
display a superior advantage because the nasal mucosa is often the initial site of infection …
被引用次数：192 相关文章

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

VP Chavda, LK Vora, AK Pandya… - Drug discovery …, 2021 - pubmed.ncbi.nlm.nih.gov
Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a
superior advantage because the nasal mucosa is often the initial site of infection. Preclinical …

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

VP Chavda, LK Vora, AK Pandya… - Drug Discovery …, 2021 - pure.qub.ac.uk
Abstract Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines
display a superior advantage because the nasal mucosa is often the initial site of infection …
[HTML] nih.gov

[HTML][HTML] Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

VP Chavda, LK Vora, AK Pandya… - Drug Discovery …, 2021 - ncbi.nlm.nih.gov
Abstract Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines
display a superior advantage because the nasal mucosa is often the initial site of infection …

Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.

VP Chavda, LK Vora, AK Pandya… - Drug Discovery …, 2021 - europepmc.org
Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a
superior advantage because the nasal mucosa is often the initial site of infection. Preclinical …